Imatinib Mesylate
31 NDCs across 14 manufacturers|28 Generic,3 Brand
Imatinib Mesylate is used to treat blast crisis, dermatofibrosarcoma, gastrointestinal neoplasms, hypereosinophilic syndrome, lymphoid leukemia and myeloid leukemia, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on May 10, 2001, and the first generic was approved Dec 3, 2015. FDA's Orange Book lists 26 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $219 million on Imatinib Mesylate across 130,000 claims for 17,000 beneficiaries.
Imatinib Mesylate is available as 31 NDCs from 14 manufacturers (28 generic, 3 brand), with NADAC prices from $0.49 to $328.03 per EA — the most expensive product costs about 668× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
31
28G / 3B
Manufacturers
14
competing in market
Price Spread
$0.49 – $328.03
per EA
7d Activity
avg -1.0% WoW · of 31 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
14 manufacturers producing IMATINIB MESYLATE(5 pricing outliers)
Frequently Asked Questions
What is Imatinib Mesylate used to treat?
Imatinib Mesylate is used to treat blast crisis, dermatofibrosarcoma, gastrointestinal neoplasms, hypereosinophilic syndrome, lymphoid leukemia and myeloid leukemia, per the National Library of Medicine's MED-RT classification.
When did Imatinib Mesylate become available as a generic?
FDA approved the first generic Imatinib Mesylate (ANDA) on Dec 3, 2015. The Orange Book currently lists 26 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Imatinib Mesylate?
In 2024, Medicare Part D spent $219 million on Imatinib Mesylate across 130,000 claims for 17,000 beneficiaries.
How many Imatinib Mesylate products are on the market?
The Imatinib Mesylate drug market contains 31 NDCs from 14 manufacturers — 28 generic and 3 brand products.
What is the price range for Imatinib Mesylate?
NADAC reference prices for Imatinib Mesylate range from $0.4912 to $328.0342 per EA — the most expensive product costs about 668× the cheapest.
Is generic Imatinib Mesylate cheaper than brand?
The average generic NADAC for Imatinib Mesylate is $1.8802 per EA, versus $248.9627 for brand-labeled products — brand versions average about 132× the generic price.
Which manufacturers make Imatinib Mesylate?
14 manufacturers list Imatinib Mesylate in NADAC. Ranked by number of NDCs, the largest are BluePoint Laboratories (4), Novartis Pharmaceuticals Corporation (3), Ascend Laboratories, LLC (2), Archis Pharma LLC (2), Quallent Pharmaceuticals Health LLC (2).
How has the price of Imatinib Mesylate changed recently?
Over the past 7 days, 0 Imatinib Mesylate NDCs rose and 21 fell, with a market-wide average change of -1.0%.